Invention Grant
US09052312B2 Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
有权
用于预测对抗肿瘤坏死因子α（TNF）治疗的反应性的生物标志物
- Patent Title: Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
- Patent Title (中): 用于预测对抗肿瘤坏死因子α（TNF）治疗的反应性的生物标志物
-
Application No.: US12740166Application Date: 2008-10-31
-
Publication No.: US09052312B2Publication Date: 2015-06-09
- Inventor: Zoltán Konthur , Hans Lehrach , Karl Skriner
- Applicant: Zoltán Konthur , Hans Lehrach , Karl Skriner
- Applicant Address: DE München
- Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Current Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Current Assignee Address: DE München
- Agency: Foley & Lardner LLP
- Priority: EP07119810 20071031
- International Application: PCT/EP2008/064820 WO 20081031
- International Announcement: WO2009/056633 WO 20090507
- Main IPC: G01N33/53
- IPC: G01N33/53 ; G01N33/564 ; G01N33/68
Abstract:
The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumor necrosis factor alpha (TNFα or TNF) treatment to assess the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or more biomarker proteins in a bodily fluid or an excrement of said patient, and sorting the individual into one of two categories based on detection of said immunoglobulin(s), wherein individuals are classified as NON-responder or responder. The invention refers to diagnostic kits comprising said one or more biomarker proteins and the use of these kits for assessing the responsiveness to an anti-TNF treatment of an individual who is to be subjected to or is being subjected to an anti-TNFα treatment.
Public/Granted literature
- US20110045490A1 BIOMARKER FOR THE PREDICTION OF RESPONSIVENESS TO AN ANTI-TUMOUR NECROSIS FACTOR ALPHA (TNF) TREATMENT Public/Granted day:2011-02-24
Information query
IPC分类:
